Ehrlich C E, Young P C, Cleary R E
Am J Obstet Gynecol. 1981 Nov 1;141(5):539-46. doi: 10.1016/s0002-9378(15)33275-0.
This study was designed to determine whether the presence of progesterone receptors (PR) and/or estradiol receptors (ER) could be used to predict progestin responsiveness of recurrent or advanced endometrial cancers. We have demonstrated the presence of physicochemically similar cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria. All normal endometria contained both PR and ER. Seventy-three percent of endometrial hyperplasias were PR(+) and 93% were ER(+). A decreasing concentration of progesterone receptor activity was observed with increasing tumor anaplasia [grade 1, 84% PR(+); grade 2, 55% PR(+); grade 3, 22% PR(+)] and in irradiated tumors. A statistically significant (p less than 0.001) relationship has been demonstrated between the presence of specific cytoplasmic PR and response to progestin therapy in recurrent or advanced endometrial adenocarcinomas. Thus, we conclude that a PR assay may be used to help select the most appropriate therapy for patients with recurrent or advanced endometrial adenocarcinoma.
本研究旨在确定孕激素受体（PR）和/或雌二醇受体（ER）的存在是否可用于预测复发性或晚期子宫内膜癌对孕激素的反应性。我们已经证实在正常、增生和癌性子宫内膜中存在物理化学性质相似的细胞质孕激素和雌二醇受体。所有正常子宫内膜均同时含有PR和ER。73%的子宫内膜增生为PR阳性，93%为ER阳性。随着肿瘤间变程度增加[1级，84% PR阳性；2级，55% PR阳性；3级，22% PR阳性]以及在接受放疗的肿瘤中，观察到孕激素受体活性浓度降低。在复发性或晚期子宫内膜腺癌中，已证实特定细胞质PR的存在与对孕激素治疗的反应之间存在统计学显著差异（p<0.001）。因此，我们得出结论，PR检测可用于帮助为复发性或晚期子宫内膜腺癌患者选择最合适的治疗方法。
